General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-14 | 2024-09 | -0.33 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.34 | -0.25 | 0.09 | 26.47% |
2024-05-09 | 2024-03 | -0.21 | -0.31 | -0.1 | -47.62% |
2024-05-09 | 2024-03 | -0.21 | N/A | N/A | N/A |
2024-03-14 | 2023-12 | 0 | N/A | N/A | N/A |
2024-03-14 | 2023-12 | 0 | -0.5 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-05-14 | HC Wainwright & Co. | Upgrade | Neutral | Neutral |
2023-03-19 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-02-22 | HC Wainwright & Co. | Upgrade | Buy | |
2022-11-13 | HC Wainwright & Co. | Upgrade | Buy | |
2022-08-14 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-22 | BROWN BRIAN LEE | Chief Financial Officer | 290.69K | Conversion of Exercise of derivative security |
2024-05-22 | DURENARD EUGENE A | Director | 115.00K | Conversion of Exercise of derivative security |
2024-05-22 | EGAN DWIGHT H. | Chief Executive Officer | 367.21K | Conversion of Exercise of derivative security |
2024-05-22 | MURPHY TED | Director | 127.50K | Conversion of Exercise of derivative security |
2024-05-22 | NELSON JAMES B | Director | 115.00K | Conversion of Exercise of derivative security |
2024-05-22 | SERBIN RICHARD S | Director | 117.50K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.78M | 1.98M | 5.79% |
2023-06-29 | Renaissance Technologies, LLC | 653.70K | 725.61K | 2.12% |
2023-06-29 | Blackrock Inc. | 506.51K | 562.22K | 1.65% |
2023-06-29 | Geode Capital Management, LLC | 302.16K | 335.39K | 0.98% |
2023-06-29 | Bridgeway Capital Management, Inc. | 272.90K | 302.92K | 0.89% |
2023-06-29 | Bank Of New York Mellon Corporation | 145.62K | 161.64K | 0.47% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.28M | 1.42M | 4.15% |
2023-06-29 | Vanguard Extended Market Index Fund | 444.78K | 493.70K | 1.44% |
2023-06-29 | Bridgeway Funds Inc-Ultra Small Company Fund | 272.90K | 302.92K | 0.89% |
2023-05-30 | Fidelity Extended Market Index Fund | 165.22K | 180.09K | 0.54% |
2023-08-30 | iShares Micro Cap ETF | 69.84K | 86.60K | 0.23% |
2023-05-30 | Fidelity Total Market Index Fund | 53.59K | 58.41K | 0.17% |
The new FDA policy permits Co-Diagnostics to begin U.S. sales of COVID-19 tests immediately while it awaits FDA clearance under Emergency Use Authorization (EUA). The Company’s application for EUA is currently under review by the FDA. It’s a go
Salt Lake City, Utah – March 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following a successful clinical evaluation of its Logix Smart COVID-19 Test, the Company will begin fulfilling orders from a wider array of U.S. customers, including thousands of additional laboratories in the country who can now run the Company’s test as a clinical diagnostic.
A recent FDA policy change aimed at expediting the availability of COVID-19 diagnostics has allowed the Company to expand domestic sales of its test immediately. Co-Diagnostics’ COVID-19 polymerase chain reaction (PCR) test can yield results in under two hours, and successfully passed the clinical evaluation as requested in the policy change, showing sensitivity of 100% and specificity of 100% in detecting SARS-CoV-2, the virus which causes COVID-19, without demonstrating any cross-reactivity with other coronaviruses.
Dwight Egan, Co-Diagnostics CEO, commented “Our Logix Smart COVID-19 test has already been deployed on a global basis to five continents as well as to U.S. CLIA labs that meet certain requirements, and we are prepared to provide an even greater number of U.S. laboratories and patients access to our test as a result of the new FDA policy. The demand for reliable, high-quality COVID-19 diagnostics has never been greater, and it continues to grow daily as this disease affects not just patients afflicted with it and their families, but the entire nation as a whole.
“We believe the excellent performance of our COVID-19 test combined with affordable pricing will place it in the vanguard of available testing alternatives worldwide. We have scaled up both our domestic and international production capabilities to meet demand, including receiving a license to manufacture our COVID-19 test in our facility in India, which more than triples our capacity. The Company’s Logix Smart COVID-19 test, built on our patented CoPrimer technology, has the potential to improve the quality of life of millions of Americans by providing access to a prompt, accurate, cost-effective test. We are gratified to be in a position to make available a test that can provide results in less than two hours, which we believe is among the fastest turn-around times of any test currently on the market.”
The new FDA policy permits Co-Diagnostics to begin U.S. sales of COVID-19 tests immediately while it awaits FDA clearance under Emergency Use Authorization (EUA). The Company’s application for EUA is currently under review by the FDA.
$BMRA Test now Exempt from FDA emergency use authorization requirement - see page 9 https://www.fda.gov/media/135659/download
$BMRA can start selling this test immediately as long as it includes the disclaimer found at page 9 of the FDA Policy
You can read more about this and other stocks at
r/CovidStocks on Reddit
Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
First Rapid, Point-of-Care and Near-Patient Molecular Test for Detection of Virus that Causes COVID-19
SUNNYVALE, Calif., March 21, 2020 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert Systems worldwide, with a detection time of approximately 45 minutes.
"During this time of increased demand for hospital services, Clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities. An accurate test delivered close to the patient can be transformative — and help alleviate the pressure that the emergence of the 2019-nCoV outbreak has put on healthcare facilities that need to properly allocate their respiratory isolation resources," said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "By leveraging the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and potential future variants of SARS-CoV-2, we have developed a test that provides reference lab-quality results in multiple settings where actionable treatment information is needed quickly."
"Cepheid currently has nearly 5,000 GeneXpert Systems in the US capable of point-of-care testing and for use in hospitals," said Cepheid President Warren Kocmond. "Our automated systems do not require users to have specialty training to perform testing — they are capable of running 24/7, with many systems already doing so today."
The test will begin shipping next week. For more information about Cepheid's Xpert Xpress SARS-CoV-2 test, please visit www.cepheid.com/coronavirus.
From codx Thanks to all of our followers, shareholders, and customers that have reached out to express concern after the earthquake in Salt Lake City this morning. Thankfully, neither the quake nor its aftershocks have affected our operations or production. Hope everyone is staying safe and healthy.
Happy to announce that following a successful clinical evaluation, #CODX can begin fulfilling #COVID19 orders from an even wider array of U.S. customers, including thousands of additional laboratories in the country who can now run the Company’s test as a clinical diagnostic.
http://codiagnostics.com/co-diagnostics-completes-successful-clinical-evaluation-for-fda-eua/